AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Graphs     Help
Perf. 1W: -15.7%- Perf. 1M: -22.8%- Perf. 3M: 3.16%- Perf Ytd: 8.95%
10 day relative perf. to stoxx600: -24.5%- 20 day relative perf. to stoxx600: -20.6%